Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Erickson Miller, Connie L ^a   Pillarisetti, Kodandaram ^a   Kirchner, Jennifer ^a   Figueroa, David J ^a   Ottesen, Lone ^b   Martin, Anne Marie ^a   Liu, Yuan ^a   Kamel, Yasser M ^b   Messam, Conrad ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; MESSENGER RNA; THROMBOPOIETIN RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; EPOR GENE; ERBB2 GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IGF1R GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MPL GENE; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; WESTERN BLOTTING;

BENZOATES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PYRAZOLES; RECEPTORS, THROMBOPOIETIN;

EID: 84866002171     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-405     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer 2012, V.2. http://www.nccn.org.
3. National Cancer Institute Breast Cancer Treatment (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/, National Cancer Institute.
4. Morgan RJ, Alvarez R, Armstrong DK, Boston B, Burger R, Chen L, Copeland L, Crispens MA, Fowler J. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer 2012, V.3. http://www.nccn.org.
5. National Cancer Institute Ovarian Epithelial Cancer Treatment (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/ healthprofessional/, National Cancer Institute.
6. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Govindan R. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer 2012, http://www.nccn.org.
7. National Cancer Institute Non-Small Cell Lung Cancer Treatment (PDQ) http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/, National Cancer Institute.
8. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollali T, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:3217-3224. 10.1200/JCO.2008.20.9114, 19433683.
9. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001, 19:1137-1146.
10. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005, 3:557-571.
11. Mughal TI. Current and future use of hematopoietic growth factors in cancer medicine. Hematol Oncol 2004, 22:121-134. 10.1002/hon.736, 15991222.
12. Beinert T. Role of supportive care in the treatment of NSCLC: supportive care for myelotoxicity. Lung Cancer 2002, 38(Suppl 3):S79-S80.
13. Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother 2008, 42:1865-1870. 10.1345/aph.1L231, 19017828.
14. Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br J Haematol 2009, 146:127-141. 10.1111/j.1365-2141.2009.07702.x, 19388936.
15. de Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996, 183:651-656. 10.1084/jem.183.2.651, 2192470, 8627177.
16. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002, 21:3359-3367. 10.1038/sj.onc.1205323, 12032774.
17. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006, 134:453-466. 10.1111/j.1365-2141.2006.06215.x, 16856888.
18. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the MPL ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995, 92:3234-3238. 10.1073/pnas.92.8.3234, 42140, 7536928.
19. Peeters K, Stassen JM, Collen D, Van Geet C, Freson K. Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today 2008, 13:798-806. 10.1016/j.drudis.2008.06.002, 18602017.
20. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009, 27:424-430. 10.1634/stemcells.2008-0366, 2729672, 19038790.
21. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009, 37(9):1030-1037. 10.1016/j.exphem.2009.06.011, 19631713.
22. Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leuk Lymphoma 1998, 30:415-431.
23. Motoji T, Takanashi M, Motomura S, Wang WH, Shiozaki H, Aoyama M, Mizoguchi H. Growth stimulatory effect of thrombopoietin on the blast cells of acute myelogenous leukaemia. Br J Haematol 1996, 94:513-516. 10.1046/j.1365-2141.1996.d01-1832.x, 8790152.
24. Murayama T, Imoto S, Natazuka T, Chihara K, Matsui T. Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO. Leuk Res 1998, 22:557-560. 10.1016/S0145-2126(98)00042-3, 9678722.
25. Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the non-peptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009, 114:3899-3908. 10.1182/blood-2009-04-219493, 2773490, 19710504.
26. Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010, 34:1224-1231. 10.1016/j.leukres.2010.02.005, 20202683.
27. Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011, 35:23-328.
28. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743. 10.1056/NEJMoa064320, 17192538.
29. Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008, 99:711-715. 10.1038/sj.bjc.6604501, 2528149, 18728660.
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
31. Erickson-Miller CL, Chadderton A, Gibbard A, Kirchner J, Pillarisetti K, Baker K, Pandite L, El-Hariry I, Mostafa Kamel Y, Liu Y, et al. Thrombopoietin receptor levels in tumor cell lines and primary tumors. J Oncol 2010 2010, Article ID 135354.
32. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009, 4:87-92. 10.1097/JTO.0b013e3181915052, 3024911, 19096312.
33. Smith JW, McIntyre KJ, Acevedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O'Shaughnessy JA. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009, 118:361-367. 10.1007/s10549-009-0410-5, 19459042.
34. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 2009, 27:2163-2169. 10.1200/JCO.2008.17.4839, 2674003, 19307510.
35. Dasanu CA, Herzog TJ, Alexandrescu DT. Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration. J Oncol Pharm Pract 2010, 16:63-66. 10.1177/1078155209105396, 19525302.
36. Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Gynecol Oncol 2009, 114:210-214. 10.1016/j.ygyno.2009.04.016, 19446320.
37. Tovari J, Pirker R, Timar J, Ostoros G, Kovacs G, Dome B. Erythropoietin in cancer: an update. Curr Mol Med 2008, 8:481-491. 10.2174/156652408785747979, 18781955.
38. Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 2008, 14:4685-4690. 10.1158/1078-0432.CCR-08-0264, 18676735.
39. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007, 110:477-488. 10.1002/cncr.22832, 17582631.
40. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009, 115:58-71. 10.1080/13813450902783106, 19485702.
41. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. 10.1056/NEJMra0801289, 19228622.
42. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47.